



Lonza

PyroCell[®] MAT HS System

Instructions for Routine Use

Cat. # 279791 contains :

Cat. # 279770 - PyroCell[®] MAT HS Kit

Cat. # 253325 - PeliKine compact human IL-6 ELISA kit

Revision A

The PyroCell® MAT Kit and the PyroCell® MAT HS Kit are Lonza Bioscience products for the Monocyte Activation Test. Components are manufactured by Sanquin Reagents B.V. for Lonza Bioscience.

The PeliKine compact human IL-6 kit and the PeliKine tool set 1 are manufactured by Sanquin Reagents B.V. and distributed by Lonza Bioscience for Monocyte Activation Test applications.

Notices

© Lonza 2022. All rights reserved.

No part of this publication may be reproduced, transcribed, or transmitted in any form, or by any means electronic or mechanical, including photocopying and recording, for any purpose other than the purchaser's use without written permission of Lonza.

Trademarks

PyroCell® is a Lonza registered trademark.

All trademarks belong to Lonza or its affiliates or to their respective third party owners.

Restrictions and liabilities

Information in this document is subject to change and does not represent a commitment by Lonza. Changes made to the information in this document will be incorporated in new editions of the publication. No responsibility is assumed by Lonza for the use or the reliability of reagents, software or equipment that are not supplied by Lonza or its affiliated dealers.

The PyroCell® MAT HS Kit has been designed and validated for reproducible detection of a variety of different pyrogens using IL-6 cytokine release as read-out for pyrogenic activity. Other cytokines may be suitable as read-out, but their use with the PyroCell® MAT HS Kit needs to be validated by the user. A reference sample with a known concentration of a pyrogen (not included) may be used for quality control purposes.

pMAT Cells are found to be reactive towards the non-endotoxin pyrogens listed in the Certificate of Analysis (CoA). pMAT Cells are responsive to multiple non-endotoxin pyrogens, the specific reactivity has to be determined by the user.

The applicable warranty for Lonza reagents and products stipulated in this use guide is found at www.bioscience.lonza.com. This warranty contains the obligations of Lonza, and no other warranties, expressed, implied, or statutory are given. Other than the express warranty contained herein, Lonza shall not be responsible for any direct or consequential damages of any kind. This warranty shall not be changed or modified in any way without the express written permission of Lonza.

Lonza and Sanquin Reagents B.V. are not liable for any claims, including third party claims, due to or caused by pyrogenic activity in pharmaceutical products. Consult the relevant chapters in the European Pharmacopoeia (Ph. Eur. 2.6.30) as well as other documents relevant for your specific purpose for utilization of the test.

Do not use reagents beyond the expiry date. The expiry date is printed on the packaging or directly on the vial. **pMAT Cells can be used for up to 6 months from the date of shipment.**

Quality control

It is considered good laboratory practice to run laboratory samples according to instructions and specific recommendations included in the instructions for use of the test to be conducted. Failure to follow these instructions may result in erroneous test data.

Safety Data Sheets (SDS) are available from the Lonza product website.

Batch-specific Certificates of Analysis are available from the Lonza website, www.lonza.com/coa.

Regulatory information

The Monocyte Activation Test (MAT) is described in the European Pharmacopeia (Ph. Eur. chapter 2.6.30) as a compendial, *in vitro* test for the detection of pyrogens in pharmaceutical preparations. The MAT is therefore, suitable as a replacement test for the Rabbit Pyrogen Test (RPT) after a product-specific validation¹.

The MAT is recognized by other world pharmacopeias such as the United States Pharmacopeia², as an alternative method to the RPT. Alternative method validation may be required.³ Please contact your local authorities for country-specific information.

Intended use statement

The PyroCell® MAT HS Kit, consisting of cryopreserved human peripheral blood mononuclear cells (PBMC) pooled from four healthy donors (pMAT Cells), and MAT Human Serum (HS) Supplement, is used as an *in vitro* assay for the detection of pyrogenic components in raw materials, intermediates, parenteral preparations or medical devices.

This PyroCell® MAT HS Kit is for laboratory use only and not intended for diagnostic purpose, detection of pyrogens in man or animal, treatment of patients or patient management.

Product support & technical service

If your Lonza product fails to function properly, if you have questions about how to use or maintain our products, or if you need to send an instrument to Lonza for repair or other service, please contact our Scientific Support.

North America

Customer Service: 800 638 8174 (toll free)

Scientific Support: 800 521 0390 (toll free)

scientific.support@lonza.com

Online ordering: bioscience.lonza.com

Europe

Customer Service: + 32 87 321 611

Scientific Support: + 32 87 321 611

scientific.support.eu@lonza.com


Online ordering: bioscience.lonza.com


For technical support for countries outside of the USA or Europe, please contact your local Lonza sales office or your regional distributor. See contact information on back cover.

Revision History

Rev	Date	Changes
A	2022	First issue


Document Conventions

	This icon identifies information that protects the safety of the operator and the integrity of data.
Warning!	A Warning indicates the potential for bodily harm and tells you how to avoid the problem.
Caution	A Caution indicates the potential for damage and tells you how to avoid the problem.

Note:	Bold text is primarily used for emphasis.
	This icon calls attention to important information.

Warnings and precautions

NOTE: All reagents described in this manual are intended for research use only.

Warning!	Not suitable for in vitro diagnostics or medical use.
Warning!	Not intended to detect pyrogens in man or animal or for diagnosis of human or animal diseases.
Warning!	Not intended for patient management.
Warning!	pMAT Cells contain traces of fetal bovine serum (FBS) sourced in North America, as a stabilizer. FBS components shall be handled in laboratory environments only.
Warning!	pMAT Cells and MAT Human Serum Supplement are derived from human blood donations. Human blood used for preparations was tested negative for human infectious disease markers. Please refer to the CoA for the pMAT Cell lot. However, primary human cells cannot be assumed to be free from infectious agents and must be handled with appropriate care.
Caution	Handle all reagents according to Good Laboratory Practice (GLP) using appropriate precautions.
Caution	Apply aseptic and non-pyrogenic handling of the PyroCell® MAT HS Kit. The MAT shall be carried out by authorized and well-trained laboratory personnel only.
Caution	PyroCell® MAT HS Kit components must be stored at $\leq -80^{\circ}\text{C}$ under controlled conditions. Temperature excursions impair the functionality of components. Thawed reagents must be used immediately and cannot be refrozen.
Caution	Do not use vials that show signs of temperature excursion such as ice crystals inside the vial or uneven surfaces. Please contact Lonza scientific support.
Caution	Do not use leaking or damaged vials.
Caution	Do not use vials of pMAT Cells where the medium color changed from pink to yellow.
Caution	Do not use reagents that show turbidity or other signs of microbial contamination.
Caution	Expiry. Do not use reagents beyond the expiry date. The expiry date is printed on the packaging or directly on the vial. pMAT Cells can be used for up to 6 month from the date of shipment
Caution	Disposal. Dispose of reagent containers according to local regulations.
	Please refer to the Safety Data Sheet (SDS) for product safety information.

Abbreviations

Abbreviation	Description
BET	Bacterial Endotoxin Test
BRP	Biological Reference Preparation
CLC	Contaminant Limit Concentration
CO ₂	Carbon dioxide
CoA	Certificate of Analysis
Complete IMDM	Iscove's Modified Dulbecco's Medium with added MAT Human Serum Supplement (included in the PyroCell® MAT HS Kit)
ELISA	Enzyme-linked Immunosorbent Assay
HS	Human serum (if used in combination with PyroCell® Kits)
Ph. Eur.	European Pharmacopeia
EU/mL	Endotoxin Units per Milliliter
EEU/mL	Endotoxin Equivalent Units per Milliliter
IL-6	Interleukin-6
HPE	High performance buffer
HRP	Horseradish peroxidase
IMDM	Iscove's Modified Dulbecco's Medium
IPA	Isopropyl Alcohol
LAL	Limulus Amebocyte Lysate
LOD	Limit of Detection
MAT	Monocyte Activation Test
MVD	Maximum Valid Dilution
mL, µL	Milliliter, Microliter
N/A	Not applicable
NEP	Non-Endotoxin Pyrogens
NM	Nanometer
OD	Optical Density
PBMC	Peripheral Blood Mononuclear Cells
Pcs	Pieces
Ph. Eur.	European Pharmacopeia
pMAT Cells	Pooled PBMC qualified for the MAT
RPT	Rabbit Pyrogen Test
RSE	Reference Standard Endotoxin
SDS	Safety Data Sheet
4-PLM	Four parameter logistic model
5-PLM	Five parameter logistic model

Table of Contents

Notices	3
Trademarks	3
Restrictions and liabilities	3
Quality control	4
Regulatory information.....	4
Intended use statement	4
Product and technical service	5
Revision history	6
Document conventions	6
Warnings and precautions	7
Abbreviations	8
1. Background – Monocyte Activation Test (MAT).....	111
2. PyroCell® MAT HS System – Assay principle	12
3. Material information and storage conditions	13
3.1 PyroCell® MAT HS Kit	13
3.1.1 Storage and stability	13
3.1.2 Package content	13
3.2 PeliKine compact human IL-6 ELISA kit.....	14
3.2.1 PeliKine compact human IL-6 kit.....	14
3.2.1.1 Storage and stability	14
3.2.1.2 Package content.....	15
3.2.1.3 Sensitivity	15
3.2.1.4 Reference standard	15
3.2.2 PeliKine tool set 1	15
3.2.2.1 Storage and stability	16
3.2.2.2 Package content.....	16
3.3 Further reagents and consumables	16
3.4 Laboratory equipment needed	17
3.5 Recommended literature	18
4. Definitions and calculations	19
4.1 Calculating the Maximum Valid Dilution (MVD) and the Contaminant Limit Concentration (CLC).....	19
4.2 Calculating the Limit of Detection (LOD).....	20

5. Test procedure	20
5.1 Use of qualified cells	20
5.2 Preparatory testing – Choosing the right method	21
5.3 Routine testing – Monocyte activation	23
5.3.1 Preparation of complete medium	24
5.3.2 Preparation of endotoxin dilutions	25
5.3.2.1 Method A.....	25
5.3.2.2 Method B	26
5.3.3 Preparation of product sample dilutions	28
5.3.4 Incubation of test samples with pMAT Cells	29
5.4 Routine testing – IL-6 ELISA.....	30
5.4.1 Preparation of working strength buffers	31
5.4.2 Overnight coating of the microtiter plate (day 1)	32
5.4.3 Preparation of cell culture supernatant dilutions	32
5.4.4 (Optional) Preparation of an IL-6 standard curve	33
5.4.5 ELISA incubation and wash steps	33
5.5 Microtiter plate absorbance reading	35
6. Analysis of results	36
6.1 Method A – Quantitative test.....	37
6.1.1 Acceptance criteria for the endotoxin standard curve	38
6.1.2 Calculation of pyrogenicity	38
6.2 Method B – Semi-quantitative test.....	39
6.2.1 Acceptance criteria	40
6.2.2 Calculation of pyrogenicity	40
6.3 Method C – Lot comparison test.....	41
6.3.1 Acceptance criteria	41
6.3.2 Calculation of pyrogenicity	41
Contact information	42

1. Background – Monocyte Activation Test (MAT)

Pyrogenic substances in parenterally administered pharmaceutical products can lead to fever, and life-threatening reactions in patients. In order to ensure patient safety, it is required to demonstrate that parenteral preparations do not contain harmful levels of pyrogens. Pyrogenic substances can originate from microorganisms such as bacteria or fungi, from viruses, or from non-organic sources such as chemicals and primary packaging materials. The most potent pyrogen is bacterial endotoxin derived from gram negative bacteria. All other pyrogens are summarized under the term non-endotoxin pyrogens (NEP). The purpose of a pyrogen test is to demonstrate that the amount of pyrogenic contaminants contained in a preparation is below the contaminant limit concentration (CLC) in order to release the product as being safe. Different tests acknowledged by regulatory agencies are available to determine whether a product or test preparation is free from pyrogenic contaminants (Fig. 1).





	Test type	Mechanism	Identification
Pyrogen	 Monocyte Activation Test (MAT) Ph. Eur. 2.6.30, USP <1085>	<i>In vitro</i> : measures inflammatory cytokines released by human blood monocytes	Bacterial endotoxins and non-endotoxin pyrogens (e.g. bacteria, viruses, yeasts and molds)
	 Rabbit Pyrogen Test (RPT) Ph. Eur. 2.6.8, USP <151>	<i>In vivo</i> : measures raise in body temperature after injection of a drug	
Endotoxin	 Recombinant Factor C Assay (rFC) Ph. Eur. 2.6.32, USP <1085>	<i>In vitro</i> : recombinant alternative to LAL. Based on factor C, the first component of the LAL clotting cascade	Specific for bacterial endotoxin (gram-negative bacteria)
	 Limulus Amebocyte Lysate (LAL) Test (= BET Assay) Ph. Eur. 2.6.14, USP <85>	<i>In vitro</i> : measures the initiation of the clotting cascade in horseshoe crab blood amebocytes by endotoxin	

Fig. 1: Compendial endotoxin and pyrogen detection methods

The **Monocyte Activation Test (MAT)** is an *in vitro* assay based on the detection of pro-inflammatory cytokines released by human blood monocytes upon stimulation with pyrogenic substances. The MAT is capable of detecting endotoxins as well as non-endotoxin pyrogens in raw materials, intermediates, process samples and manufactured products. The MAT has been qualified and validated by the European Center for the Validation of Alternative Methods (ECVAM) in 2005² and by the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)³ in 2008. It has been adopted by some main pharmacopeias, for example, the European Pharmacopeia (Ph. Eur. Chapter 2.6.30)¹ as a compendial method and is considered to be suitable, after a product-specific validation, to replace the rabbit pyrogen test (RPT)¹. Other pharmacopeias describe the MAT as an alternative method to the RPT. For example, the United States Pharmacopeia (USP) requests the MAT to be validated according to USP <1225>^{4,5}. Please contact your local authorities for more information.

2. PyroCell[®] MAT HS System – Assay Principle

The PyroCell[®] MAT HS System measures a response of the human innate immune system. Monocytes, the key cells of innate immunity, respond to the presence of pyrogens (endotoxin and non-endotoxin pyrogens) by secreting pro-inflammatory cytokines, which can be measured by an Enzyme-Linked Immunosorbent Assay (ELISA). On the day of the experiment, the pMAT Cells are thawed and incubated with the product or test samples in an overnight cell culture at 37°C in a humidified cell incubator. On the next day, the cell culture supernatants are harvested and the cytokine interleukin-6 (IL-6) released by the monocytes is detected with the PeliKine compact human IL-6 ELISA kit. Presence of IL-6 is then measured in an absorbance reader as optical density (OD). Using a standard curve generated with reference standard endotoxin (RSE), the OD values are finally converted into Endotoxin Equivalent Units (EEU/mL).




Fig. 2: Monocyte Activation Test - Assay overview

3. Material Information and Storage Conditions

The PyroCell® MAT HS System (# 279791) combines reagents to conduct the MAT in a ready-to-use kit. The following materials are included: the PyroCell® MAT HS Kit (# 279770) and the PeliKine compact human IL-6 ELISA kit (# 253325, comprising the PeliKine compact human IL-6 kit (Sanquin, M1916) and the PeliKine tool set 1 (Sanquin, M1980).

3.1 PyroCell® MAT HS Kit

pMAT Cells are manufactured and qualified according to the compendial requirements of Ph. Eur. chapter 2.6.30. Each preparation of pMAT Cells is generated by pooling equal amounts of peripheral blood mononuclear cells (PBMC) isolated from four qualified human blood donations, and subsequent cryopreservation of the pooled PBMC under controlled conditions. Please refer to the Certificate of Analysis (CoA) for more information on quality assurance.

To ensure traceability, each vial of pMAT Cells is labelled with two codes; the first code (68-XXXX) refers to the original production lot number (lot org) which can also be found on the CoA. The second code (P-XXX) refers to the individual vial. The lot number of the MAT Human Serum Supplement is printed on the vial label, and on the CoA.

3.1.1 Storage and stability



- **Important! Components of the PyroCell® MAT HS Kit need to be stored at $\leq -80^{\circ}\text{C}$.** Temperature excursion will impair the functionality of the vial content.
- **Important!** Components cannot be re-frozen after thawing and must be used immediately.
- **Important!** pMAT Cells expiry is 6 months from the shipment date.
- Consult the CoA for additional information.

3.1.2 Package content

Amount	Component	Closure	Volume	Lot #
3 vials	pMAT Cells (M2016LC)	Green	3 x 1 mL	68-xxxx (Lot org.)
3 vials	MAT Human Serum Supplement (M2017LS)	White	3 x 2 mL	8000-xxxxxx

3.2 PeliKine compact human IL-6 ELISA kit

The PeliKine compact human IL-6 ELISA kit is (# 253325) comprised of two reagent kits, the PeliKine compact human IL-6 kit (M1916) and the Pelikine tool set 1 (M1980).



- Only use reagents and microtiter plates supplied with the PeliKine compact human IL-6 kit. Do not mix reagents from different lots.
 - Sodium azide inactivates the horseradish peroxidase (HRP). Do not use solutions containing sodium azide, nor add sodium azide to the supplied materials.
 - All reagents contains merthiolate (0.001% w/v).
 - Mix all reagents thoroughly before use (avoid foaming).
 - Briefly spin all vials prior to use to prevent reagent loss (1 min at 3000 x g).
 - Do not allow wells to stand uncovered or dry for extended periods of time between incubation steps. Cover plate with adhesive seal.
-

3.2.1 PeliKine compact human IL-6 kit (M1916)

The PeliKine compact human IL-6 kit is a "sandwich-type" enzyme immunoassay. The target cytokine IL-6 is bound to a pre-coated microtiter plate and is detected by an enzymatic reaction forming a colored product in proportion to the amount of cytokine present in the sample.

3.2.1.1 Storage and stability

Store the PeliKine compact human IL-6 kit at -18°C to -32°C. The expiration date is shown on the box label. Do not use reagents beyond the expiration date.

Store the prepared HPE buffer (working strength buffer) at 2 to 8°C in closed containers and use within 1 week. Bring the buffer to room temperature (18 to 25°C) prior to use (also see table 3.2.2.1).

3.2.1.2 Package content

The PeliKine compact human IL-6 kit contains all material sufficient for 3 plates (288 tests). The following reagents are included:

Amount	Component	SDS	Closure	Volume	Concentrate
1 vial	Coating antibody		Red	375 µL	100x
1 vial	Blocking reagent		Transparent	2 mL	50x
1 vial	Biotinylated antibody		Yellow	375 µL	100x
1 vial	Streptavidin-poly-HRP conjugate		Brown	20 µL	10,000x
1 vial	IL-6 standard		Black	750 µL	See label
1 bottle	HPE buffer	▲	Transparent	55 mL	5x
3 pcs	96-well microtiter plate with lid		-	-	-
10 pcs	Plate seals		-	-	-

3.2.1.3 Sensitivity

The assay sensitivity can be increased by using a horizontal plate shaker at 700 ± 100 rpm for all incubations including the enzymatic color development. The limit of detection (LOD) can be calculated as follows:

Mean calculated zero signal + 3 SD: 0.2 – 0.4 pg/mL (shake or static incubation)

3.2.1.4 Reference standard

The recombinant human IL-6 standard has been calibrated against the WHO International Standard (IL-6 89/548)⁶; National Institute for Biological Standards and Control, Potter Bar, Hertfordshire, U.K. 1 WHO Unit = 10 pg IL-6.

3.2.2 PeliKine tool set 1 (M1980)

The PeliKine tool set 1 completes the PeliKine compact human IL-6 kit by providing all chemicals and solutions used for the PeliKine compact human IL-6 ELISA: coating and washing buffers, as well as substrate and stop solutions.



- Only use reagents from one set. Do not mix reagents from different lots.
- Do not add any preservative to the reagents. Preservatives may impair the color development of the HRP substrate system.
- The washing buffer contains merthiolate (0.001% w/v). Handle with appropriate care.
- Avoid exposure of TMB substrate solution and stop solution to metals or metal ions to prevent unintended color formation.


3.2.2.1 Storage and stability

- Store the PeliKine tool set 1 at 2 to 8°C. The expiration date is shown on the box label. Do not use reagents beyond the expiration date.
- Store prepared buffers (working strength buffer) at 2 to 8°C in closed containers and use within the time frame and temperature indicated in the table below.

Reagent (ready-to-use)	Storage	Application
Coating buffer	2 to 8°C, up to 1 week	18 to 25°C
PBS solution	2 to 8°C, up to 1 week	18 to 25°C
Washing buffer	2 to 8°C, up to 2 months	18 to 25°C
(HPE buffer, M1916)	2 to 8°C, up to 1 week	18 to 25°C)

3.2.2.2 Package content

The PeliKine tool set 1 contains all materials sufficient for one PeliKine compact human IL-6 kit (288 tests, 3 plates). The following reagents are included:

Amount	Component	SDS	Volume	Preparation
1 bottle	Coating buffer capsules		3 pieces	3 x 100 mL buffer
1 bottle	PBS tablets		3 pieces	3 x 200 mL buffer
2 bottles	Washing Buffer		2 x 50 mL	2 x 1 L buffer
1 bottle	TMB substrate solution		40 mL	Ready-to-use
1 bottle	Stop solution		40 mL	Ready-to-use

3.3 Further reagents and consumables

Reagents in the table below are recommended for use with the PyroCell® MAT HS System. Alternative reagents may be used however, their suitability for the intended purpose needs to be verified.

Reagent	Volume	Cat. #
Iscove's Modified Dulbecco's Medium (IMDM)	500 mL	12-722F
Reference standard endotoxin (RSE), e.g. preparations from USP or EP (BRP)	10,000 U	E700 (USP)
Sterile, non-pyrogenic water (LAL water) for reconstitution of RSE	100 mL	W50-100
Distilled or deionized water for buffer preparation	1250 mL	N/A
(optional) Two relevant non-endotoxin pyrogens	N/A	refer to CoA

The following standard laboratory consumables shall be appropriate for cell culture and endotoxin testing, i.e. they need to be sterile and non-pyrogenic:

Consumable	Volume	Cat. #
Borosilicate glass tubes	30 pcs/pack	N207
(optional) De-pyrogenated sample container	25 pcs/box	80-507U
Reagent Reservoirs, non-pyrogenic	10 pcs/pack	00190035
96-well flat bottom microplates (cell culture)	50 pcs/pack	25-340
Pipette tips, non-pyrogenic	as appropriate	See Catalog
Polystyrene disposable pipettes	as appropriate	See Catalog
96-well round bottom untreated microplates for harvesting the cell culture supernatant	as appropriate	See Catalog
Conical polypropylene centrifuge tubes, 50 mL	as appropriate	See Catalog

3.4 Laboratory equipment needed

The following equipment is required to conduct the assay:

Equipment	Step
Freezer (-80°C or lower, alarm setting)	Storage of PyroCell® MAT HS Kit
Freezer (-20°C or lower)	Storage of PeliKine compact human IL-6 kit
Refrigerator (2 to 8°C)	Storage of PeliKine Tool Set 1 Storage of working strength buffer
Laminar airflow cabinet with HEPA filter	Aseptic preparation of cell culture plate
CO ₂ -incubator (humidified, 37°C, 5% CO ₂)	Overnight incubation of cell culture plate
Water bath, 37°C	Controlled thawing of pMAT Cells
Vortex mixer	Preparation of Reference Standard Endotoxin (RSE)
Adjustable multichannel pipettor (30-300 µL)	Preparation of cell culture and ELISA plate
Adjustable pipettors for accurate delivery of liquid volumes (diverse, 1-1000 µL)	Reagent preparation, preparation of the cell culture plate and ELISA plate
Beakers, flasks, cylinders	Preparation and storage of working strength buffer for ELISA
(optional) Device for delivery of washing buffer	Supports washing steps for the ELISA
(optional) Automated microplate washer	Supports washing steps for the ELISA
(optional) Microplate shaker	Increases sensitivity of the ELISA
Microplate reader, e.g. ELx808™ reader containing a 450nm filter and a 550nm (540-590 nm) reference filter	Cat. # 25-315S ELISA assay read-out

3.6 Recommended literature

1. European Directorate for the Quality of Medicines (EDQM). *European Pharmacopeia chapter 2.6.30: Monocyte Activation Test*, Edition 9
2. European Centre for Validation of Alternative Methods (ECVAM), 2006: *In Vitro Pyrogen Test using Human Whole Blood/IL-6*. Test method validation report (TM 2002-05)
3. Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), 2008: *Validation Status of Five In Vitro Test Methods Proposed for Assessing Potential Pyrogenicity of Pharmaceuticals and Other Products*. Test method evaluation report (NIH No. 08-6392)
4. United States Food and Drug Administration (FDA), 2012: *Guidance for Industry Pyrogen and Endotoxins Testing: Questions and Answers*
5. United States Pharmacopeia (USP), 2007: *Validation of Compendial Procedures <1225>*. Rockville, MD. USP 41–NF:1-5.
6. RE Gaines Das, S Poole: *The International Standard for interleukin-6*. Evaluation in an International Collaborative Study *J Immunol Methods* (1993) 160(2):147-53.
7. Helle M, Boeije L, de Groot E, de Vos A, Aarden L: *Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera*. *J.Immunol.Methods*. 1991 Apr 8;138(1):47-56.
8. Molenaar-de Backer, M. W. A., Gitz, E., Dieker, M., Doodeman, P. and ten Brinke, A. (2021) "Performance of monocyte activation test supplemented with human serum compared to fetal bovine serum", *ALTEX - Alternatives to animal experimentation*, 38(2), pp. 307–315. doi: 10.14573/altex.2008261.
9. Solati S, Aarden L, Zeerleder S, Wouters D: *An improved monocyte activation test using cryopreserved pooled human mononuclear cells*. *Innate Immunity*. 2015 Oct;21(7):677-84.

4. Definitions and Calculations

The terms cut-off value and LOD represent the same information but use different units. The cut-off value is expressed in the unit of response, i.e. optical density (OD) while the LOD is expressed as a concentration, e.g. EU/mL.



Important! Historical data of the PyroCell® MAT HS Kit suggest an LOD ≤ 0.08 EU/mL if used with the PeliKine compact human IL-6 ELISA.

Important! Endotoxin concentrations stated throughout this use guide, such as LOD, are calculated as concentration per sample. The concentration in the reaction well of the cell culture plate is half of the stated concentration, e.g. half LOD. Use the LOD per sample to calculate the MVD of the product to be tested.

Important! Consult the Certificate of Analysis for additional information.

The MAT is used to demonstrate that the amount of pyrogenic contaminants in the product tested does not exceed the contaminant limit concentration (CLC). To assure that the CLC can be detected in the assay, it is necessary not to exceed the Maximum Valid Dilution (MVD) based on the limit of detection (LOD) of the test system.

4.1 Calculating the Maximum Valid Dilution (MVD) and the Contaminant Limit Concentration (CLC)

The Maximum Valid Dilution (MVD) is defined as the maximum allowable dilution of a product or test sample at which the contaminant limit can be determined.¹

The MVD is calculated using the following expression:

$$MVD = \frac{CLC \times C}{LOD}$$

CLC = Contaminant Limit Concentration (e.g. EU/mg).

C = Concentration of test solution (e.g. mg/mL).

LOD = Limit of Detection (e.g. EU/mL) for the sample.

The CLC is calculated using the following expression:

$$CLC = \frac{K}{M}$$

K = Threshold pyrogenic dose per kilogram of body mass (e.g. EU/kg).

M = Maximum recommended bolus dose of product per kilogram of body mass (e.g. mg/kg).

4.2 Calculating the Limit of Detection (LOD)

The LOD is determined by the mean value of the replicates of the responses to the blank and the endotoxin standard curve. The LOD is the concentration in Endotoxin Units per milliliter (EU/mL), corresponding to the cut-off value of the measured response (optical density, OD). The cut-off value is calculated using the following expression¹:

$$\text{cutoff value} = x + (3s)$$

x = mean of the four replicates of the response of the blank

s = standard deviation of the four replicates of the responses to the blank

According to the European Pharmacopeia each user has to establish the LOD in their laboratory based on the current experiment or historical data¹. Using the PyroCell® MAT HS Kit combined with the PeliKine compact human IL-6 ELISA kit an LOD of ≤ 0.08 EU/mL per sample can be expected. Consult the Certificate of Analysis (CoA) for additional information.

5. Test Procedure

5.1 Use of qualified cells

pMAT Cells contained in the PyroCell® MAT HS Kit consist of a cryopreserved pool of human peripheral blood mononuclear cells (PBMC) serving as the monocytic cell source¹ for the MAT. PBMCs are isolated from blood donations of healthy volunteers. Blood donors are qualified to satisfy the criteria described in Ph. Eur. chapter 2.6.30, section 5.3 prior to blood donation. All donations are tested negative for common infectious disease marker. On the day of donation equal amounts of PBMC from four donors are pooled and cryopreserved in a controlled-rate freezer within a validated time frame as of the blood donation. After thawing, the pMAT Cells are qualified with the PeliKine compact human IL-6 ELISA kit for conformance to section 5-5 of Ph. Eur. chapter 2.6.30 and to meet the criteria outlined in section 6-1 and 6-3 regarding the reactivity towards reference standard endotoxin (RSE) and non-endotoxin pyrogens (NEP). In addition, the averaging effect of pooling is considered by comparing the reactivity of the pool and each of the four individual donors towards endotoxin. For details on the individual cell lot please consult the respective certificate of analysis (CoA).

On the day of the experiment the pMAT Cells are thawed and immediately diluted in complete medium to achieve the optimal cell concentration per reaction well.

5.2 Preparatory testing - Choosing the right method

Before proceeding to routine testing of a product with MAT, preparatory testing (= product-specific validation) should be performed (Fig. 3).¹ Preparatory testing is required to establish the preparation of the endotoxin standard curve in the laboratory, to confirm that the specific product to be examined does not interfere with the assay, or that interference can be overcome by product dilutions not exceeding the MVD of the product. It further assures that both bacterial endotoxin and non-endotoxin pyrogens (NEP) are detected. Finally, testing of three manufactured product lots using the optimal product dilutions determined during product validation confirms the choice of the appropriate MAT method (method A – Quantitative test, method B – Semi-quantitative test, or method C – Reference lot comparison test).




Fig. 3: Preparatory testing requirements.

An endotoxin standard curve prepared from reference standard endotoxin (RSE, # E700) is required for preparatory testing and for method A.¹ It is used to convert the OD signal measured for product samples into endotoxin equivalent units (EEU). Establish the endotoxin standard curve by performing the MAT on 7 ascending RSE dilutions, and a blank (negative control). Prepare each dilution in 4 replicates on a 96-well microtiter plate.

For data analysis, choose an appropriate regression model for curve fitting. For the PyroCell[®] MAT HS Kit a 5-parameter logistic model (5-PLM) is recommended. Lonza is offering an excel based analysis template as an easy-to-use tool that automatically performs all necessary calculations. For more information on data analysis please also refer to section 6.

Once the endotoxin standard curve is established or if method B is used during routine testing, we recommend to use 5 endotoxin reference dilutions in order to fit more test samples on the same microtiter plate.

The test for interfering factors requires a positive product control (PPC, endotoxin spike at a concentration at the middle of the standard curve) to be recovered from product dilutions within the range of 50-200% of the spike.¹ All product dilutions shall not exceed the MVD for the product in order to ensure that the contaminant can still be detected at the CLC. If product interferences cannot be overcome by dilution, method C is recommended over methods A and B.

Each product dilution, the endotoxin dilutions, and the blank are prepared in 4 replicates on a 96-well microtiter plate. Determine the appropriate product dilution as follows:

- Prepare dilutions for the endotoxin standard curve.
- Prepare geometric dilutions of the product with all dilutions not exceeding the MVD.
- For all product dilutions, generate a PPC by spiking with an endotoxin concentration near the estimated middle of the standard curve, i.e. 0.32 EU/mL (method A) or twice the LOD, i.e. 0.16 EU/mL (method B).
- Test the dilution series with and without PPC in the same experiment on the same microtiter plate.
- Calculate the mean recovery of the spiked endotoxin by subtracting the mean concentration of dilutions without endotoxin from PPC dilutions. Compare to the expected values by using the endotoxin standard curve.
- Determine the highest product sample concentration with a valid spike recovery.

Within the same experiment, evaluate the dilution series of the product to be parallel to the endotoxin standard curve. If this is not the case, use of method B is recommended.




Fig 4: Simplified decision tree to support the choice of the MAT method.

Test the system reactivity towards NEP by using either a historic product batch with NEP contaminants (or elicited a positive response in the rabbit pyrogen test) or use at least two different NEP ligands for toll-like receptors that may reflect the highest risk for the product. At least one relevant NEP ligand should be spiked into the highest valid concentration of the test product that was determined during interference testing, and must be recovered within the range of 50-200% of the spike. It is recommended to test commercial NEPs for absence of bacterial endotoxin, e.g. with a BET prior to use.

Finally, use the highest valid test product concentration to exclude interference of the product with the chosen read-out system.¹ OD values obtained in the IL-6 ELISA for an IL-6 standard dilution series in the presence and absence of the product preparation should not differ by more than 20%.

Based on the results from preparatory testing, select the suitable method for routine testing:

- Method A: Quantitative test
- Method B: Semi-quantitative test
- Method C: Reference lot comparison test

For Method C, the dilution of the product and the reference lot depends on the type of analysis used to make the comparison between the two and is determined by the user.

5.3 Routine testing - Monocyte activation



- **Important!** Ensure aseptic handling of cells. Use sterile, endotoxin-free materials only.
 - **Important!** Adhere to GCCP (good cell culture practices). Work in a laminar airflow cabinet, wear gloves, and clean the exterior of equipment and materials with disinfectant, e.g. 70% isopropyl alcohol (IPA) prior to use.
 - Refer to Ph. Eur., chapter 2.6.30 for description of MAT test methods.
-

Stimulation of pMAT Cells with product is carried out by an overnight cell culture step at $37 \pm 1^\circ\text{C}$ in an appropriate atmosphere (5% CO₂, humidified air). The stimulation period shall allow for sufficient accumulation of the IL-6 cytokine and is typically achieved within 18-24h. The response to the product sample is then compared to the response towards RSE (Endotoxin standard curve, method A or geometric dilutions, method B), or to a reference lot of the same product (method C).

5.3.1 Preparation of complete medium



- Ensure sterility of the IMDM, e.g. by using an unopened bottle.
 - **Important!** A minimum of 1 mL IMDM without MAT Human Serum Supplement is needed for the first RSE dilution. Preparing the first RSE dilutions with complete medium may result in an inaccurate endotoxin standard curve.
 - Equilibrate the complete medium to room temperature (18 to 25 °C).
-

The complete medium used for the pMAT cell incubation consists of IMDM with added MAT Human Serum Supplement (M2017LS) that is included in the PyroCell® MAT HS Kit.

1. Thaw the **MAT Human Serum Supplement** vial in a water bath at 37°C.
2. Add the entire vial content (2 mL) to a sterile, non-pyrogenic 50 mL tube containing 38 mL IMDM.
3. Mix gently by inverting the closed tube. **Use the complete medium within 8 hours.**

5.3.2 Preparation of reference endotoxin dilutions



- **Important!** Prepare all endotoxin dilutions shortly before the experiment.
 - **Important!** Do not vortex samples containing complete medium to prevent the formation of air bubbles.
 - Vortex the RSE stock solution (2,000 EU/mL) for 30 min before use.
-

Reference endotoxin dilutions are used to determine the LOD of the test system and to estimate the amount of pyrogen in test sample. Include reference endotoxin dilutions, and a blank on each microtiter plate. Each dilution is prepared in 4 replicates.

When working with the PyroCell® MAT HS kit we recommend to prepare a standard curve with 7 endotoxin dilutions, and a blank for the quantitative test method A, and 5 endotoxin dilutions, and a blank for the semi-quantitative test method B. Example plate layouts are illustrated in **Fig 5**.

	1	2	3	4	5	6	7	8	9	10	11	12
A												
B	1.28 EU/mL	0.64 EU/mL	0.32 EU/mL	0.16 EU/mL								
C	(R7)	(R6)	(R5)	(R4)								
D												
E												
F	0.08 EU/mL	0.04 EU/mL	0.02 EU/mL	Blank								
G	(R3)	(R2)	(R1)	(R0)								
H												

	1	2	3	4	5	6	7	8	9	10	11	12
A												
B	0.64 8xLOD	0.32 4xLOD	0.16 2xLOD									
C	(R5)	(R4)	(R3)									
D												
E												
F	0.08 LOD	0.04 1/2 LOD	Blank									
G	(R2)	(R1)	(R0)									
H												

Fig. 5: (A) Suggested plate layout for method A (R0-R7). (B) Suggested plate layout for method B (R0-R5). Concentrations are based on a historical LOD of ≤ 0.08 EU/mL.

Prepare an endotoxin stock solution of 2,000 Endotoxin Unit (EU)/mL by following the user instructions:

1. Add 5 mL of endotoxin-free LAL water to a vial of RSE (Lonza # E700).
2. Reconstitute RSE by vortexing for 30 min at maximum speed. The resulting solution (2,000 EU/mL) is the stock solution.

Use 50 μ L stock solution to prepare endotoxin dilutions for one 96-well microtiter plate. Aliquots of the stock solution can be stored frozen at -80°C for future use. Upon thawing vortex the aliquot for 3 min before use.

5.3.2.1 Method A


Prepare a serial dilution starting at 1.28 EU/mL with two-fold dilutions down to 0.02 EU/mL (1.28 – 0.64 – 0.32 – 0.16 – 0.08 – 0.04 – 0.02 EU/mL), and a blank in sterile, non-pyrogenic borosilicated glass tubes (# N207) as described below (also refer to **Fig 6A**):

3. Add 50 μ L of RSE stock solution (2000 EU/ mL) to 950 μ L **IMDM** (WITHOUT MAT CULTURE MEDIUM SUPPLEMENT). The final concentration is 100 EU/mL. Vortex thoroughly for 3 min.
4. Add 80 μ L of 100 EU/mL RSE dilution to 920 μ L **complete medium**. The final concentration is 8 EU/mL. Mix by pipetting up and down 10x, with a volume of at least 500 μ L.

Do not vortex samples containing complete medium and prevent the formation of air bubbles as this may decrease the cells' reactivity towards endotoxin.

5. Add 160 μ L of 8 EU/mL RSE dilution to 840 μ L **complete medium**. The final concentration is 1.28 EU/mL. Mix by pipetting up and down 10x, with a volume of at least 500 μ L.
6. Add 200 μ L of 1.28 EU/mL endotoxin to wells A1 to D1 (see **Fig 5**).

7. Add 100 μL of **complete medium** to the other wells used for the standard curve (E1-H1, A2-H2, A3-H3, and A4-H4).
8. Make a two-fold dilution by pipetting 100 μL from R7 (1.28 EU/mL, A1-D1) to R6 (0.64 EU/mL, A2-D2) using a multi-channel pipettor with 4 lines. Mix thoroughly by pipetting up and down 10x. **Prevent the formation of air bubbles.**
9. Repeat dilution as described in point 6 for transferring 100 μL from R6 to R5 (A3-D3), from R5 to R4 (A4-D4), from R4 to R3 (E1-H1), from R3 to R2 (E2-H2), and from R2 to R1 (E3-H3). Discard the final 100 μL from R1.
10. Save the remaining 8 EU/mL RSE solution prepared at step 2 for preparation of endotoxin spiked samples (see section 5.3.3 and **Fig. 6A**).



Aliquot RSE, 2,000 EU/ml in LAL water	50 μL RSE, (2,000 EU/mL) in 950 μL IMDM	80 μL RSE, (100 EU/mL) in 920 μL complete medium	160 μL RSE, (2 EU/mL) in 840 μL complete medium	160 μL RSE, (100 EU/mL) in 1840 μL complete medium
Upon thawing, vortex for 3 min	Vortex 3 min	Mix by pipetting up and down n 10x	Mix by pipetting up and down n 10x	Mix by pipetting up and down n 10x
2,000 EU/mL	100 EU/mL	8 EU/mL	1.28 EU/mL	0.64 EU/mL

Fig. 6A: Serial dilution for method A. Prepare 1.28 EU/mL endotoxin dilution and 0.64 EU/mL spike solution.

5.3.2.2 Method B

Prepare a dilution series starting at 0.64 EU/mL with two-fold dilutions down to 0.04 EU/mL (0.64 – 0.32 – 0.16 – 0.08 – 0.04 EU/mL), and a blank in sterile, non-pyrogenic borosilicated glass tubes (# N207). An example for a dilution series is shown in **Fig 6B** below:

Proceed with the preparation of endotoxin dilutions:

1. Add 50 μL of RSE stock solution (2000 EU/ mL) to 950 μL of **IMDM** (WITHOUT MAT CULTURE MEDIUM SUPPLEMENT). The final concentration is 100 EU/mL. Vortex thoroughly for 3 min.

2. Add 40 μL of 100 EU/mL RSE dilution to 960 μL of **complete medium**. The final concentration of 4 EU/mL. Mix thoroughly by pipetting up and down 10x, with a volume of at least 500 μL .

Do not vortex samples containing complete medium and prevent the formation of air bubbles as this may decrease the cells' reactivity towards endotoxin.

3. Add 160 μL of 2 EU/mL RSE dilution to 840 μL of **complete medium**. The final concentration of 0.64 EU/mL. Mix thoroughly by pipetting up and down 10x, with a volume of at least 500 μL .
4. Add 200 μL of 0.64 EU/mL endotoxin to wells A1 to D1 (see fig 5).
5. Add 100 μL of **complete medium** to the other wells used for the standard curve (E1-H1, A2-H2 and A3-H3).
6. Make a two-fold dilution by pipetting 100 μL from R5 (0.64 EU/mL, A1-D1) to R4 (0.32 EU/mL, A2-D2) using a multi-channel pipettor with 4 lines. Mix thoroughly by pipetting up and down 10x. **Prevent the formation of air bubbles.**
7. Repeat dilution as described in point 6 for transferring 100 μL from R4 to R3 (A2-D2), from R3 to R2 (E1-H1) and R2 to R1 (E2-H2). Discard the final 100 μL from R1.
8. Save the remaining 4 EU/mL RSE solution prepared at step 2 for preparation of endotoxin spiked samples (see section 5.3.3 and **Fig. 6B**).




Fig. 6B: Serial dilution, prepare 0.64 EU/mL endotoxin dilution and 0.32 EU/mL spike solution.

5.3.3 Preparation of product sample dilutions



- **Important!** Prepare the product sample on the day of the experiment.
- **Important!** Prepare RSE dilutions in borosilicated glass tubes
- Using the example layout below, 2-3 product preparations can be tested on a single plate

For routine application of Method A (quantitative) and Method B (semi-quantitative) it is requested to fit the following preparations on the same 96-well plate: A fresh preparation of an endotoxin standard curve (method A) or endotoxin dilutions (method B) and three dilutions of a product preparation, each measured with and without an endotoxin spike. Each dilution is tested in 4 replicates suggesting 2 different samples fitting on a plate if method A is used and 3 different samples for method B. Optional, an NEP control can be prepared. Examples for a plate layout for method A and B with one product sample is given below (**Fig. 7**):

	1	2	3	4	5	6	7	8	9	10	11	12
A												
B	1.28 EU/mL	0.64 EU/mL	0.32 EU/mL	0.16 EU/mL	S1	S1-1/2	S1-1/4					
C	(R7)	(R6)	(R5)	(R4)								
D												
E				Blank	S1 +	S1-1/2 +	S1-1/4 +					
F	0.08 EU/mL	0.04 EU/mL	0.02 EU/mL		RSE spike	RSE spike	RSE spike					
G	(R3)	(R2)	(R1)	(R0)								
H												

	1	2	3	4	5	6	7	8	9	10	11	12
A												
B	0.64 8xLOD	0.32 4xLOD	0.16 2xLOD		S1	S1-1/2	S1-1/4					
C	(R5)	(R4)	(R3)									
D												
E			Blank		S1 +	S1-1/2 +	S1-1/4 +					
F	0.08 LOD	0.04 1/2 LOD			RSE spike	RSE spike	RSE spike					
G	(R2)	(R1)	(R0)									
H												

Fig. 7: Suggested plate layout for the quantitative (A) or semi-quantitative (B) MAT method. Endotoxin reference standards with concentrations in EU/mL (A, R0 – R7) or x LOD (B, R0 – R5). Sample (S1) in 2 successive two-fold dilutions (S1-1/2 and S1-1/4) without and with spiked endotoxin (PPC, row E-H, indicated by darker color). The spike concentration should be near the middle or the standard curve for method A (0.32 EU/mL) or at 2x LOD for method B (0.16 EU/mL).

1. Add 200 μ L of the product test sample S1-1 (highest concentration with valid PPC recovery, determined during preparatory testing) in wells A5 to H5 (Method A), or A4 to H4 (Method B).
2. Add 100 μ L of complete medium into the other wells used for the sample dilutions.
3. Prepare a two-fold dilution by pipetting 100 μ L from S1 to S1-1/2 and mix by pipetting up and down 10x. Prevent formation of air bubbles.
4. Repeat for transfer from S1-1/2 to S1-1/4 and discard the final 100 μ L.
5. If a further samples are to be tested: repeat step 1-4 for each additional sample.

6. Add 50 μL of complete medium to endotoxin dilutions and product test samples without an endotoxin spike.
7. Prepare the endotoxin spike solution (PPC) from the saved dilutions of step 5.3.2.1 or 5.3.2.2, respectively.

Method A: Add 160 μL of 8 EU/mL endotoxin to 1840 μL complete medium. The final concentration is 0.64 EU/mL.

Method B: Add 160 μL of 4 EU/mL endotoxin to 1840 μL complete medium. The final concentration is 0.32 EU/mL.

Mix by pipetting up and down 10x, with a volume of at least 1 mL.

Do not vortex! Prevent formation of air bubbles.

8. Add 50 μL of the PPC preparation to wells for spiked samples (Ex to Hx, marked with + RSE spike).

Method A: The endotoxin spike concentration in the sample corresponds to 0.32 EU/mL value from the standard curve.

Method B: The endotoxin spike concentration in the sample corresponds to the endotoxin dilution with 0.16 EU/mL.

5.3.4 Incubation of test samples with pMAT Cells



- **Important!** Appropriate handling of cryopreserved cells is critical to maintain full functionality of the cells.
 - **Important!** Ensure aseptic handling of cells. Adhere to GCCP (good cell culture practices). Work in a laminar airflow cabinet, wear gloves, and clean the exterior of equipment and materials with disinfectant, e.g. 70% isopropyl alcohol (IPA) prior to use.
-

1. Take one vial of pMAT Cells from the -80°C freezer. **Immediately thaw the vial in a water bath at 37°C until a small clump of ice remains visible (< 5 min).**
2. Transfer the entire contents of the vial (1 mL) into a 50 mL conical tube and immediately but slowly add 5 mL complete medium (equilibrated to room temperature) while gently swirling the tube (< 5 min). **Do not vortex or vigorously pipet, take care not to form air bubbles.**
3. Transfer mixture to a sterile reservoir and transfer 50 μL of the suspended pMAT Cells to each well containing prepared test dilutions using a multi-channel pipette with 8 lines.
4. Incubate the microplate with lid in a CO_2 -incubator at 37°C (humidified air, 5% CO_2) for 18-24 hours.

5. On the next day, harvest 100-150 μL of the supernatant by carefully placing the pipette tip at the side of the well. Avoid turbulence to leave the pMAT Cells at the bottom of the plate. Transfer the supernatant to a fresh 96-well round bottom, untreated microplate

Only part of the supernatant is used for a routine ELISA (see section 5.4.3), the remaining supernatant can be stored frozen at $\leq 20^{\circ}\text{C}$ for future experiments. The storage time of the frozen supernatant may be product-dependent and needs to be determined by the user.

5.4 Routine testing - IL-6 ELISA



- Adhere to GLP (good laboratory practices) for ELISA. An ELISA can be performed on a regular laboratory bench.
 - **Important!** The pMAT Cells have been validated using the PeliKine compact human IL-6 ELISA kit.
-

The PeliKine compact human IL-6 ELISA kit is a "sandwich-type" enzyme immunoassay in which a monoclonal anti-IL-6 antibody is pre-coated to polystyrene microtiter wells. The IL-6 cytokines contained in the cell culture supernatant are bound by the IL-6 antibody on the microtiter plate. Unbound material is removed by washing. Subsequently, a biotinylated antibody is added. This antibody binds to the cytokine-antibody complex present in the microtiter well. Excess biotinylated antibody is removed by washing, followed by addition of horseradish peroxidase (HRP) conjugated streptavidin, which binds onto the biotinylated side of the cytokine sandwich. After removal of unbound streptavidin-HRP conjugate by washing, a substrate solution is added to the wells.

A colored product is formed in proportion to the amount of cytokine present in the sample or standard. After the reaction is terminated by the addition of a stop solution, the absorbance is measured in a microtiter plate reader. The absorbance (optical density, OD) of the reference endotoxin dilutions is then plotted against the concentration (EU/ mL) and resulting standard curve is used to calculate the concentration of the contaminant in the product samples (see section 6). The contaminant concentration is expressed in endotoxin equivalent units (EEU).

For more information about the PeliKine compact human IL-6 kit you may also refer to the package insert of the kit as well as to the original instructions for use for the PeliKine compact human IL-6 kit (Sanquin, M1916) and PeliKine tool set 1 (Sanquin, M1980).

5.4.1 Preparation of working strength buffers



- All buffers provided with the PeliKine tool set 1 are concentrates. Working strength buffers may be prepared prior to the day of experiment. For storage information of working strength buffers refer to section 3.2.2.1 “storage information”.
- All volumes stated refer to one ELISA plate. Coating of the supplied ELISA plate with coating antibody must be performed at least 1 day prior to conducting the ELISA.
- Substrate solution contains a mixture of hydrogen peroxide and 3,3',5,5'-tetramethylbenzidine (TMB). Protect the substrate solution from prolonged exposure to light.
- Protect TMB substrate solution and stop solution from contact with metal or metal ions. This may lead to unspecific color formation.
- The TMB substrate solution should be color-less. Do not use TMB substrate solution that appears blue. Replace solution.



Stop solution contains sulfuric acid solution (0.18 M) in water.

Consult the SDS for Product Safety Information.

Reagent	Buffer Preparation
Coating buffer	Dissolve contents of one capsule in 100 mL of distilled water. Incubate 5 min, mix contents. Do not dissolve or rinse the outer capsule as this will interfere with the functionality of the coating buffer.
PBS solution	Dissolve one PBS tablet in 200 mL of distilled water. Incubate 5 min, mix contents.
Washing buffer	Dissolve 50 mL of the concentrate in 950 mL of distilled water.
HPE buffer	Dissolve 15 mL of the concentrate in 60 mL of distilled water, mix contents.
TMB Substrate Solution	Ready-to-use.
Stop Solution	Ready-to-use.

5.4.2 Overnight coating of the microtiter plate (day 1)



- **Important!** Equilibrate coating antibody and working strength coating buffer to 18 to 25°C prior to use.

Preparation	Add to each wells	Incubation
<ul style="list-style-type: none"> • Prepare working strength coating buffer (see section 5.4.1). • Dilute 120 µL coating antibody (red cap) in 12 mL coating buffer. • Mix by inverting the tube 10 times. 	<ul style="list-style-type: none"> • 100 µL of coating antibody solution. • Cover plate with a lid. 	<ul style="list-style-type: none"> • Overnight at 18 to 25°C.

5.4.3 Prepare dilutions of the cell culture supernatants



- Harvest the cell culture supernatant as described in section 5.3.4.
- The optimal dilution can vary between different test products and may be determined by the user.
- **Important!** When using the PeliKine compact human IL-6 ELISA kit, a 5- fold supernatant dilution of all harvested supernatants is recommended. Less dilution, e.g. 3-fold will increase the accuracy for the lowest concentrations of reference endotoxin dilutions which likely leads to a lower experimental LOD. At the same time however, more concentrated endotoxin preparations may be outside the reader's detection range.
- The protocol below refers to a 1:5 dilution of the cell culture supernatant which is providing the largest dynamic range.

- Pipette 100 µL of HPE buffer into each well of a fresh, round bottom 96-well microtiter plate (= HPE plate).
- Homogenize the harvested supernatants by pipetting up and down 5 times. Add 25 µL of cell culture supernatant to the corresponding well on the HPE plate and mix by pipetting.

5.4.4 (Optional) Preparation of an IL-6 standard curve



- An IL-6 standard curve may be included as quality control for the IL-6 ELISA, and for method C (may replace reference endotoxin dilutions). It is not required to determine the pyrogenic activity if method A or B are used.
 - Adding an IL-6 standard curve requires 1-2 “empty” columns on the microtiter plate.
-

Preparation of an IL-6 standard curve is optional for routine MAT. The IL-6 standard curve will contain 450, 150, 50, 16.7, 5.6, 1.9, 0.6 and 0 pg/mL IL-6 in HPE buffer.

- Label 7 tubes, one tube for each dilution: 450, 150, 50, 16.7, 5.6, 1.9 and 0.6 pg/mL.
- Pipette 497 μ L of working-strength HPE buffer into the tube for 450 pg/mL.
- Pipette 400 μ L of working strength dilution buffer into all other tubes.
- Transfer 63 μ L of the IL-6 standard (4000 pg/mL, black cap) into the first tube for 450 pg/mL. Mix well.
- Transfer 200 μ L of this dilution into the second tube labelled 150 pg/mL.
- Repeat the serial dilution steps by adding 200 μ L of the previous tube of diluted standard to the 400 μ L of dilution buffer. Mix well.

5.4.5 ELISA incubation and wash steps



- Equilibrate all buffers and antibody dilutions to 18 to 25°C before use.
 - Keep the streptavidin-HRP conjugate at -18 to -32°C to ensure stability. Thaw shortly before use.
 - Always empty wells completely before adding a new solution. A plate washer is recommended for all wash steps.
 - Mix contents in wells by tapping the edge of the microtiter plate for a few seconds. Alternatively, use a plate shaker at 700 \pm 100 rpm.
 - Before preparing the working-strength buffer, briefly warm the buffer concentrate to 37°C in a water bath to dissolve any precipitates.
 - Avoid repeated freeze-thawing of the IL-6 standard. Up to 3 freeze-thaw cycles have no effect on the IL-6 levels of the IL-6 standard.
-

Preparation (1 plate)	Add to each well	Incubation/ Wash
Continue from step 5.4.2 “coating of microtiter plate”		
Wash with PBS	≥ 300 µL PBS (working strength).	4 times.
Blocking <ul style="list-style-type: none"> Dilute 500 µL blocking reagent (transparent cap) in 25 mL PBS. Mix by inverting the tube 10 times. 	<ul style="list-style-type: none"> Add 200 µL blocking buffer dilution. Cover plate with adhesive seal. 	1 hour at 18 to 25°C. Prepare supernatant dilutions.
Wash with washing buffer	≥ 300 µL washing buffer (working strength).	5 times.
Supernatant dilutions (1:5) <ul style="list-style-type: none"> Pipette 100 µL of HPE buffer (working strength) into each well of a fresh, round bottom 96 well microtiter plate (= HPE plate). Homogenize the harvested supernatant by pipetting up and down 5 times. Add 25 µL to the HPE plate and mix by pipetting up and down. 	<ul style="list-style-type: none"> Add 100 µL of supernatant dilutions. (Optional), add IL-6 standard dilutions (see section 5.2.4). Cover plate with adhesive seal. 	1 hour at 18 to 25°C. Prepare biotinylated antibody dilution immediately before wash step.
Wash with washing buffer	≥ 300 µL washing buffer (working strength).	5 times.
Biotinylated antibody <ul style="list-style-type: none"> Dilute 120 µL biotinylated antibody (yellow cap) in 12 mL HPE buffer (working strength). Mix by inverting tube 10 times. 	<ul style="list-style-type: none"> Add 100 µL of biotinylated antibody dilution. Cover plate with adhesive seal. 	1 hour at 18 to 25°C. Prepare streptavidin-HRP conjugate dilution immediately before wash step.
Wash with washing buffer	≥ 300 µL washing buffer (working strength).	5 times.
Streptavidin-HRP conjugate <ul style="list-style-type: none"> Dilute 1.2 µL streptavidin-HRP (brown cap) conjugate in 12 mL of HPE buffer (working-strength). Mix by inverting tube 10 times. 	<ul style="list-style-type: none"> Add 100 µL of Streptavidin-HRP conjugate dilution. Cover plate with adhesive seal. 	30 min at 18 to 25°C. Equilibrate TMB substrate solution and stop solution to 18 to 25°C before wash step.
Wash with washing buffer	≥ 300 µL washing buffer (working strength).	5 times.

Preparation (1 plate)	Add to each well	Incubation/ Wash
TMB substrate solution <ul style="list-style-type: none"> Ready to use. 	<ul style="list-style-type: none"> 100 μL TMB substrate solution (ready to use). Cover plate with adhesive seal. <p>Protect TMB substrate from exposure to light!</p>	10 min at 18 to 25°C in the dark, e.g. use a drawer. <p>Do not cover plate with aluminum foil!</p>
Stop solution <ul style="list-style-type: none"> Ready to use. 	Add 100 μ L of stop solution.	The color is stable for max. 30 min.

5.5 Microtiter plate absorbance reading



- The absorbance reader must be equipped with a 450 nm filter and a reference wavelength filter between 540 and 590 nm. We recommend the ELx808™ Absorbance Reader (Lonza # 25-315S) with a 450 nm filter and a 550 nm reference filter.
 - If the substrate reaction appears too intense, reduce the incubation time. Do not dilute the TMB substrate.
 - If WinKQCL® Software is used, perform a “quick-read” at each recommended wavelength. Export the data into the MAT Analysis Tool.
-
- Place the microtiter plate in an ELISA reader and record absorbance (OD) at 450 nm, and at a reference wavelength (e.g. 550 nm).
 - Subtract the reference wavelength measurement at 550 nm from the measurement at 450 nm before proceeding with further analysis of the ELISA data. For some software packages this may be performed automatically.

6 Analysis of Results



- The analysis and interpretation of MAT data depend on the chosen MAT method. Refer to Ph. Eur. chapter 2.6.30 for a detailed description¹.
 - Any appropriate software available in-house or on-line may be used for the analysis of MAT data.
 - The software CombiStats, developed by the European Directorate for the Quality of Medicines and Healthcare (EDQM, www.edqm.eu) may assist you in statistical analysis according to the Ph. Eur chapter 5.3.
 - Lonza offers an Excel-based MAT Analysis Tool to assist in the analysis of MAT data. Please contact Lonza scientific support for more information.
-

Product-specific validation is providing the basis for choosing the appropriate MAT method for testing and data analysis (see section 5.2). It ensures that the validity criteria for the respective test method are met. An overview on how to assess the pyrogen content in a product sample is given below:

1. For each sample dilution, calculate the net absorbance values by subtracting the reference OD550 nm reading from the OD450 nm reading.
2. (optional) Remove outliers caused by documented deviations to work instructions, e.g. pipetting errors.
3. (optional) Apply a sound statistical method to identify outliers within each group of replicates (e.g. Dixon method with 90 to 99% Q-critical value).
4. Calculate the average OD value for each test replicate.
5. Perform a log transformation of the OD values.
6. Plot the OD values on the y-axis and the RSE values on the x-axis and perform a regression.
7. With the regression equation calculate the concentration of each product dilution.
8. Multiply the obtained endotoxin concentration with the dilution factor of the product sample to obtain the contaminant concentration in the sample.
9. Determine the LOD (see section 4).

It is recommended to set a limit for the acceptable relative standard deviation (max. %CV, e.g. $CV \leq 25\%$) of the replicates of each dilution in order to identify potential issues during data acquisition that lead to variability in results.

For statistical evaluation of the MAT, logistic regression models like the 4-parameter logistic model (4-PML) or 5-parameter logistic model (5-PML) are most frequently used. Bioassays, e.g. ELISA, usually start as an asymptote at low doses, increase linear into an “S”-shaped curve, and end up at another asymptote at high doses meaning that they are only linear across a specific range of concentration magnitudes. While the 4-PLM is used for a symmetrical curve, the 5PLM is used if the curve from one asymptote to the other is not symmetrical. For statistical data analysis with the PyroCell® MAT HS system, a 5-PML model is recommended.

6.1 Method A – Quantitative test



- **Important!** If the basal release of the IL-6 cytokine measured in the blank is $OD \geq 0.1$, inappropriate handling of the pMAT Cells or an assay contamination with a pyrogen is indicated. Make sure to use materials tested for low endotoxin content, critically assess procedures and the environment when preparing the assay, and repeat the experiment with fresh, endotoxin-free materials.
 - The “historical LOD” is defined as the endotoxin concentration that reproducibly shows an OD reading above the cut-off value with different batches of pMAT Cells. Initially, it is recommended to use the historical LOD for calculating, e.g. the MVD of the product. The LOD may be adjusted based on laboratory data or the current experiment.¹
 - When applying method A, the analysis software used should be capable to demonstrate that (1) the regression of response on \log_{10} dose is statistically significant ($p < 0.01$), and (2) the regression of response on \log_{10} dose does not deviate significantly from linearity ($p > 0.05$ (see Ph. Eur. chapter 2.6.30 and 5.3 “Statistical analysis” for more information)).
-

Method A is based on the conversion of the OD signals for the product dilutions tested into a contaminant concentration (EEU/ mL) using the endotoxin standard curve. After applying the dilution factor correction, the contaminant concentration of the undiluted product (EEU/mL) is compared to the CLC for that product. Routine testing of products with method A is performed with the highest product concentration that was demonstrated for a valid spike recovery in preparatory testing (see section 5) and two additional 2-fold dilutions of this dilution not exceeding the MVD. Each dilution is tested on the same microtiter plate with and without an endotoxin spike at or near the middle of the standard curve.

First data inspection of the average OD of the endotoxin standard curve dilutions should confirm ascending OD values with increasing endotoxin concentrations. All OD values of endotoxin dilutions must be greater than the OD value of the blank.

- Perform a log transformation and plot the average net absorbance (mean OD_{450nm} – OD_{550nm}) of the endotoxin dilutions against their concentrations.
- Using an appropriate analysis tool, e.g. the Lonza MAT Analysis template, a dose-response curve is fitted through the data points.
- Determine the LOD (see section 4).




Fig. 8A: Typical sigmoidal 7-point endotoxin standard curve obtained with the PyroCell® MAT HS Kit and the PeliKine compact human IL-6 ELISA as a read-out system.

6.1.1 Acceptance criteria

Applying method A requires that the endotoxin standard curve meets certain statistical fit criteria that are used as curve acceptance specifications (system suitability). Furthermore, method A should be applied only upon demonstration that the dose-response curve of the product is parallel to the dose-response curve of the endotoxin reference standard (sample suitability).

- **Blank:** the average of blank should be ≤ 0.1 OD.
- **LOD:** the experimental LOD \leq historical LOD.
Example: If the historical LOD of the PyroCell® MAT HS Kit (0.08 EU/mL) is used to calculate the MVD of the product, the test is valid if LOD ≤ 0.08 EU/mL.
- **Dose response:** the dose-response of the product dilutions must be parallel to the Endotoxin Standard Curve.
- **Goodness of fit** (statistical evaluation of the fitted curve):
Confirm the quality of the standard curve by statistical analysis:
 - Regression of responses (appropriately transformed if necessary) on log₁₀ dose shall be statistically significant ($p < 0.01$).
 - Regression of responses on log₁₀ dose must not deviate significantly from linearity ($p > 0.05$).

6.1.2. Calculation of the pyrogen content

- For each sample dilution not exceeding the MVD, calculate the endotoxin spike recovery. Dilutions with an invalid spike recovery (outside the range of 50-200%) are excluded from further analysis.
- For each valid sample dilution, the OD value is converted in EEU/mL, corrected with the dilution factor and compared to the CLC.
 - If value in EEU/ml in the pure sample is $< \text{CLC}$ \rightarrow PASS.
 - If value in EEU/mL in the pure sample is $> \text{CLC}$ \rightarrow FAIL.
 - If an NEP PPC is used it has to be detected above the cut off value.

6.2 Method B - Semi-quantitative test



-
- **Important!** If the basal release of the IL-6 cytokine measured in the blank is $\text{OD} \geq 0.1$, inappropriate handling of the pMAT Cells or an assay contamination with a pyrogen is indicated. Make sure to use materials tested for low endotoxin content, critically assess preparation procedures and repeat the experiment with endotoxin-free materials.
 - The term “historical LOD” is defined as the endotoxin concentration that reproducibly demonstrates an OD reading above the cut-off value with different batches of pMAT Cells. It is recommended to use the historical LOD for necessary calculations, e.g. the MVD of the product.
-

Method B compares the OD signal of the product sample with the CLC of the product. Sample data below the cut-off value is considered negative (= pass, meaning a pyrogen level below CLC). Routine testing of products with method B is performed with highest concentration that was been demonstrated for a valid spike recovery in preparatory testing (see section 5) and two additional 2-fold dilution of this dilution not exceeding the MVD. Each dilution is tested on the same plate with and without an endotoxin spike at 2x LOD.

First data inspection of the averages of the reference endotoxin dilutions (0.5x, 1x, 2x, and 4x historical LOD) should confirm increasing OD values with increasing endotoxin concentrations. OD values found for endotoxin dilutions with concentrations equal to or higher than the historical LOD must be above the blank. The 0.5x LOD concentration can be higher than or equal to the blank.

- Plot the average net absorbance (mean $\text{OD}_{450\text{nm}} - \text{OD}_{550\text{nm}}$) of the endotoxin dilutions against endotoxin concentrations.
- Read the endotoxin content of product samples and confirm a valid spike recovery.
- Determine the LOD (see section 4).




Fig. 8B: Typical sigmoidal 5-point endotoxin standard curve obtained with the PyroCell® MAT HS Kit and the PeliKine compact human IL-6 ELISA as a read-out system.

6.2.1 Acceptance criteria

The following criteria must be valid:

- **Blank:** the average of blank should be ≤ 0.1 OD.
- **LOD:** The experimental LOD \leq historical LOD.
Example: the historical LOD of the PyroCell® MAT HS Kit is used to calculate the MVD of the product. The test is valid if $\text{LOD} \leq 0.08$ EU/mL. The mean OD signal for the endotoxin standard solutions at 1xLOD should be above the cut-off value.
- **Dose response:** the mean response of 4 endotoxin standard dilutions should increase progressively with increasing concentrations.

6.2.2 Calculation of pyrogen content

- For each product dilution not exceeding the MVD, the endotoxin spike recovery (PPC) is calculated. Dilutions with an invalid spike recovery (outside the range of 50-200%) are excluded from further analysis.
- For each valid product dilution the OD value is compared to the cut-off value. If the OD is below the cut-off value the pyrogen concentration is considered to be below the LOD of the detection system.
 - OD value (product dilution) < Cut-off value \rightarrow Pass (pyrogen level of the undiluted sample is below CLC).
 - OD value (product dilution) > Cut-off value \rightarrow not conclusive (a contamination is present in the undiluted sample but the pyrogen level cannot be evaluated with respect to the CLC).
 - OD value (product dilution at MVD) > Cut-off value \rightarrow Fail (Pyrogen level is above CLC).

6.3 Method C - Lot comparison test

Method C is comparing the OD signals or IL-6 contents from 3 dilutions of the product to be examined to a reference lot of the same formulation or the same class of formulation. A reference lot must be carefully justified. Ideally, clinical data is available. The OD ratio of the product should not exceed a justified acceptance criterion which is defined by the user. For a lot comparison samples of the reference lot and the lot to be evaluated must be tested on the same plate.

6.3.1 Acceptance criteria

The positive control and at least one dilution of the reference lot should be above the mean OD value of the blank. Ph. Eur. 2.6.30 recommends that a lot difference should not be higher or lower than 2.5-fold to pass the test.

6.3.2 Calculation of pyrogenicity

For each sample an OD ratio is calculated, corresponding to the sum of the mean response of the 3 dilutions of the lot being examined divided by the sum of the mean response of the 3 dilutions of the reference lot.

- OD ratio < acceptance criterion → pass (lot examined not pyrogenic as compared to the reference lot).
- OD ratio > acceptance criterion → fail (lot examined pyrogenic as compared to the reference lot).

Contact information

North America

Customer Service: +1 800 638 8174 (toll free)

Fax: +1 301 845 8338

order.us@lonza.com

Scientific Support: +1 800 521 0390 (toll free)

scientific.support@lonza.com

Online ordering: bioscience.lonza.com

Europe

Customer Service: + 32 87 321 611

order.europe@lonza.com

Scientific Support: + 32 87 321 611

scientific.support.eu@lonza.com

Online ordering: bioscience.lonza.com

International

Contact your local Lonza distributor

Customer Service: +1 301 898 7025

scientific.support.eu@lonza.com

International offices

Australia	+ 61 1300 657 508
Belgium	+ 32 87 321 611
Brazil	+ 55 11 4028 8000
China	+ 86 21 6305 8866
France	0800 91 19 81 (toll free)
Germany	0800 182 52 87 (toll free)
India	+ 91 124 6052941
Japan	+ 81 3 6264 0660
Singapore	+ 65 6521 4379
The Netherlands	0800 022 4525 (toll free)
United Kingdom	0808 234 97 88 (toll free)

Lonza Walkersville, Inc. – Walkersville, MD 21793

All trademarks belong to Lonza, registered in USA, EU or CH or to third party owners and used only for informational purposes. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied concerning the use of these products. The buyer assumes all risks of use and/or handling. Any user must make his own determination and satisfy himself that the products supplied by Lonza Group Ltd or its affiliates and the information and recommendations given by Lonza Group Ltd or its affiliates are (i) suitable for intended process or purpose, (ii) in compliance with environmental, health and safety regulations, and (iii) will not infringe any third party's intellectual property rights. The user bears the sole responsibility for determining the existence of any such third party rights, as well as obtaining any necessary licenses. For more details: www.lonza.com/legal.

© 2022 Lonza. All rights reserved. RT-MN035 03/22

lonza.com/mat